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Background and importance A higher incidence of 
venous thromboembolism [both pulmonary embolism and 
deep vein thrombosis (DVT)] in patients with coronavirus 
disease 2019 (COVID-19) has been described. But little 
is known about the true frequency of DVT in patients who 
attend emergency department (ED) and are diagnosed 
with COVID-19.
Objective We investigated the incidence, risk factors, 
clinical characteristics and outcomes of DVT in patients 
with COVID-19 attending the ED before hospitalization.
Methods We retrospectively reviewed all COVID 
patients diagnosed with DVT in 62 Spanish EDs (20% of 
Spanish EDs, case group) during the first 2 months of 
the COVID-19 outbreak. We compared DVT-COVID-19 
patients with COVID-19 without DVT patients (control 
group). Relative frequencies of DVT were estimated in 
COVID and non-COVID patients visiting the ED and 
annual standardized incidences were estimated for both 
populations. Sixty-three patient characteristics and four 
outcomes were compared between cases and controls.
Results We identified 112 DVT in 74 814 patients with 
COVID-19 attending the ED [1.50‰; 95% confidence 
interval (CI), 1.23–1.80‰]. This relative frequency 
was similar than that observed in non-COVID patients 
[2109/1 388 879; 1.52‰; 95% CI, 1.45–1.69‰; odds ratio 
(OR) = 0.98 [0.82-1.19]. Standardized incidence of DVT was 
higher in COVID patients (98,38 versus 42,93/100,000/
year; OR, 2.20; 95% CI, 2.03–2.38). In COVID patients, the 
clinical characteristics associated with a higher risk of 
presenting DVT were older age and having a history of 
venous thromboembolism, recent surgery/immobilization 
and hypertension; chest pain and desaturation at ED 
arrival and some analytical disturbances were also more 
frequently seen, d-dimer >5000 ng/mL being the strongest. 
After adjustment for age and sex, hospitalization, ICU 
admission and prolonged hospitalization were more 
frequent in cases than controls, whereas mortality was 
similar (OR, 1.37; 95% CI, 0.77–2.45).
Conclusions DVT was an unusual form of COVID 
presentation in COVID patients but was associated with 
a worse prognosis. European Journal of Emergency 
Medicine 28: 218–226 Copyright © 2021 Wolters Kluwer 
Health, Inc. All rights reserved.
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Introduction
Infection by severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) is mainly characterized by fever and 
respiratory symptoms, with dyspnea and lung infiltrates 
being present in more than 50% of hospitalized cases [1]. 
A significant number of other signs and symptoms can 
be present, involving the gastrointestinal tract, hepatic 
inflammation, myalgia and rhabdomyolysis [1–3]. The 
association of systemic coagulation activation is particu-
larly frequent in coronavirus disease 2019 (COVID-19), 
especially in severe cases [1–5]. The hemostatic abnor-
mality most consistently observed in COVID-19 is 
increased D-dimers in the blood stream, which is asso-
ciated with a higher risk of requiring mechanical ventila-
tion, ICU admission and death [6]. The character of this 
coagulopathy is quite prothrombotic with a high risk of 
venous thromboembolism (VTE) [7,8]. Several studies 
have shown an increased incidence of VTE, involving 
both pulmonary embolism and deep vein thrombosis 
(DVT) in patients admitted to ICUs, with cumulative 
incidences of up to 35% [9–12]. In general ward hospi-
talization, a recent study [11] described an incidence of 
asymptomatic DVT in COVID patients similar to that 
reported in other studies on asymptomatic DVT in non-
COVID patients [13]. The largest study included 338 
COVID patients, 61 of whom were admitted to an ICU 
and reported thromboembolic events in 7.7% of cases, 
with a cumulative rate of 21% [4]. The authors noted that 
half of the VTE events were diagnosed after 24 h of hos-
pital admission. In this scenario, it is difficult to quantify 
the real association of DVT with the pathogenesis of the 
disease caused by SARS-CoV-2 infection, because the 
appearance of DVT may be favored by the fact that hospi-
talized patients are usually bedridden, multidrug-treated 
and in very poor condition. In addition, irregular initia-
tion of thromboprophylaxis during the COVID-19 pan-
demic makes it more difficult to interpret the real risk of 
DVT associated with COVID-19 itself.
Bearing this uncertainty in mind, in the present study, we 
aimed to investigate the incidence of DVT in patients 
attending the emergency department (ED) before hospi-
talization and treatment with anticoagulants and specific 
drugs for SARS-CoV-2 infection. The specific objectives 
were: (1) to estimate the relative frequency and annual 
standardized incidence of DVT in patients with COVID-
19; (2) to uncover the risk factors associated with the 
development of DVT in patients with COVID-19 and 
(3) to investigate the outcomes of COVID patients pre-
senting DVT.
Methods
Study design and setting
This was a retrospective, case–control, ED-based, mul-
ticenter study that reviewed the medical reports of 
COVID-19 patients attended at Spanish EDs who were 
diagnosed as having objective DVT during ED assess-
ment and management, before hospitalization (cases). 
In Spain, the first case of SARS-CoV-2 infection was 
detected on 31 January 2020 and, accordingly, the defini-
tion of the COVID-19 period for patient inclusion in the 
present study was set from 1 March 2020 to 30 April 2020. 
During this 61-day period, 213 435 cases of COVID-19 
were confirmed by the Spanish Ministry of Health [14].
The present study forms part of the Unusual 
Manifestations of COVID-19 (UMC-19) project, which 
was designed to investigate the potential relationship 
between COVID-19 and 10 different entities that could 
be influenced by SARS-CoV-2 infection itself and for 
which at least one case had been published, suggesting 
a potential link with this viral infection. The main objec-
tives of the UMC-19 project were common for all 10 enti-
ties, and consisted in the description of the incidence, 
risk factors, clinical characteristics and outcomes for each 
particular entity (cases).
The investigators of the UMC-19 project initially con-
tacted 152 Spanish EDs, which roughly constitute half 
of the 312 hospital EDs of the Spanish public health net-
work. Of these, 81 were interested in participating and 
analyzed the protocol, and 62 finally consented to partici-
pate and duly sent all the data required (Fig. 1). These 62 
hospitals provide a quite balanced representation of the 
Spanish territory (12 of the 17 Spanish autonomous com-
munities were represented), type of hospitals (commu-
nity, reference and high-technology university hospitals 
were included) and involvement in the pandemic (with 
EDs attending from 1–47% of ED census corresponding 
to COVID patients during the COVID outbreak period).
These EDs have a reference population of 15.5 mil-
lion people, which constitutes about 33% of the whole 
Spanish population (46.9 million) [15,16].
The present study was formed by two different parts 
to cover the objectives. The first part, covering specific 
objective 1, was related with the estimation of relative 
frequency and annual standardized incidence of DVT in 
ED comers and population and comparisons with figures 
in non-COVID comers and population. With this pur-
pose, we collected the ED census in March/April 2020 
(COVID period) and distinguish between COVID and 
non-COVID patients, as well as the ED census in March/
April 2019 (pre-COVID period), all corresponding to non-
COVID patients, in order to take into account potential 
differences in ED comers due to pandemic lockdown. 
The number of DVT diagnosis performed at the ED at 
each period and patients’ group was recorded.
The second part, covering specific objectives 2 and 3, 
compared risk factors, clinical characteristics and out-
comes in COVID patients with and without DVT. The 
diagnosis of COVID-19 was based on SARS-Cov-2 
antigen detection in a nasopharyngeal swab by reverse 
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transcriptase PCR (RT-PCR), a clinically compatible 
clinical picture (including at least malaise, fever and 
cough) or the presence of the typical lung parenchymal 
infiltrates in chest X-ray or pulmonary computerized 
tomography (CT) in patients with some clinical symp-
toms attributable to COVID-19. The case group (COVID 
patients with DVT) was formed by patients diagnosed 
with DVT during the ED stay. The diagnosis was based 
on complete compression Doppler ultrasound (CCUS) of 
the legs, which included the proximal and distal territory, 
performed by a radiologist. The control group (COVID 
patients without DVT) was formed by selecting three 
COVID patients without DVT for every case detected 
by each center. Selection was randomly performed by the 
inclusion of the three COVID patients seen immediately 
before or after each case included by the center. This 
group was specifically designed to uncover the risk fac-
tors for DVT development in COVID patients.
Independent variables
We collected 63 independent variables, which included 
2 demographic data (age and sex), 6 risk factors for 
DVT (estrogen use, previous history of DVT, surgery/
immobilization previous month, active cancer, obesity 
and smoking habit), 10 comorbidities (hypertension, 
dyslipidemia, diabetes mellitus, coronary artery disease, 
cerebrovascular disease, chronic obstructive pulmonary 
disease, chronic liver disease, asthma, chronic kidney dis-
ease – creatinine >2 mg/dL – and dementia), 17 symp-
toms recorded at ED arrival (time elapsed from symptom 
Fig. 1
Study design and inclusion flow chart.
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onset to ED attendance, fever, rhinorrhea, cough, expec-
toration, dyspnea, chest pain, syncope, hemoptysis, leg 
pain/edema, abdominal pain, vomiting, diarrhea, confu-
sion, headache, anosmia and dysgeusia), 5 vital signs at 
ED arrival (temperature, systolic blood pressure, heart 
rate, respiratory rate and room air pulsioxymetry), 15 lab-
oratory parameters [C-reactive protein, creatinine, aspar-
tate aminotransferase, bilirubin, lactate dehydrogenase 
(LDH), procalcitonin, hemoglobin, leucocyte, lympho-
cyte and platelet counts, activated partial thromboplas-
tin time, prothrombin time, fibrinogen, and D-dimer], 4 
radiological findings in chest X-ray (cardiomegaly, lung 
interstitial infiltrates, ground-glass opacities and patchy 
shadowing, and pleural effusion), 3 findings in pulmonary 
CT (pulmonary embolism, lung interstitial infiltrates and 
lung ground-glass parenchymal opacities) and location of 
DVT in CCUS (proximal, distal or both).
Outcomes
We defined four different outcomes for cases and con-
trols, which consisted of: (1) the need for hospitalization; 
(2) the need for ICU admission; (3) prolonged hospitali-
zation (considered if length of hospitalization from ED 
arrival to discharge was longer than 7 days, which is the 
median length of hospitalization in Spain) and (4) in-hos-
pital all-cause mortality.
Statistical analysis
Discrete variables were expressed as absolute values 
and percentages, and continuous variables median and 
interquartile range if not normally distributed. Relative 
frequency of DVT was expressed per thousand (‰) of 
COVID or non-COVID patients coming to the ED, and 
annual standardized incidence was expressed per 100 000 
COVID or non-COVID individuals. Both estimations 
were made with 95% confidence intervals (CI) that were 
calculated using the exact method for binomial distribu-
tions. To estimate COVID and non-COVID population 
in each ED catchment area, we used the seroprevalence 
of SARS-CoV-2 in the province where the ED is placed. 
These detailed seroprevalences have been determined in 
a wide Spanish study performed between 27 April 2020 
and 11 May 2020 and have been recently reported [17].
Differences between case and control groups were 
assessed by the chi-square test (or Fisher’s exact test if 
needed) for qualitative variables, and the Mann–Whitney 
nonparametric for quantitative variables. The magnitude 
of associations remaining statistically significant after 
such correction was expressed as the unadjusted odds 
ratio (OR) with 95% CI, that were calculated by logis-
tic regression independently comparing all cases with all 
control A patients. The magnitude of the associations was 
expressed as unadjusted OR with 95% CI, and for these 
estimations, the continuous variables were dichotomized 
using clinically meaningful cutoffs or values around the 
median. As the number of cases expected to be identi-
fied was not large, we did not plan to go further in the 
investigation of the significant relationships identified in 
the unadjusted analysis by using adjusted models. The 
only exception was outcomes, which were adjusted for 
age and sex. In all comparisons, statistical significance 
was accepted if the P value was <0.05 or if 95% CI of 
the risk estimations excluded value 1. The analyses were 
performed with the SPSS (v.24) statistical software pack-
age (IBM, Armonk, New York, USA).
Ethics
The UMC-19 project was approved by the ethics com-
mittee of the Hospital Clínic of Barcelona (Spain), with 
the reference number HCB/2020/0534, that acted as the 
central ethical committee. Under the exceptional cir-
cumstances generated by the COVID-19, and taking into 
account the urgent need to obtain feasible data related 
to this new disease, and the noninterventional and ret-
rospective nature of the project, the need to obtain 
written permission from patients to be included in the 
study was waived. All patients were codified by investi-
gators of the participating centers before entering their 
data into the general database, and thus, patient identity 
remained anonymous for investigators who analyzed the 
database. The UMC-19-S
8
 was carried out in strict com-
pliance with the Declaration of Helsinki principles. The 
authors designed the study, gathered and analyzed the 
data, vouched for the data and analysis, wrote the article 
and decided to publish.
Results
Relative frequency and standardized incidence
A total of 74 814 (15‰) patients with COVID-19 were 
seen in the 61 Spanish EDs participating in the UMC-
19-S
8
 (Fig. 1) during the 61-day study period. We iden-
tified 112 DVT in COVID-19 patients and constituted 
the case group. The control group was formed by 336 
randomly selected COVID patients without DVT 
(COVID-19 non-DVT) during the same period based on 
a case–control ratio of 3:1. Confirmation of COVID-19 
infection by RT-PCR was performed in 71.4 and 73.2% 
of cases and controls, respectively. In total 28.6% cases 
and 26.8% controls were diagnosed by a clinically com-
patible clinical picture (including at least malaise, fever 
and cough) or the presence of the typical lung parenchy-
mal infiltrates in chest X-ray or pulmonary CT in patients 
with some clinical symptoms attributable to COVID-19.
Totally 1 388 879 non-COVID-19 patients were seen dur-
ing the 122-day period (497 967 during the 61 days in the 
2020 COVID-19 period and 965 726 during the 61 days 
in the 2019 pre-COVID-19 period). Of them, 2109 were 
diagnosed with DVT (797 during COVID-19 period 
and 1312 during pre-COVID-19 period). Accordingly, 
relative frequency for DVT in COVID-19 patients was 
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1.50‰ (95% CI, 1.23–1.80) and relative frequency for 
DVT in non-COVID-19 patients was 1.52‰ (95% CI, 
1.45–1.69) [with relative frequencies of 1.36‰ (95% CI, 
1.29–1.43) and 1.88‰ (95% CI, 1.76–2.02) when COVID-
19 and pre-COVID-19 periods were analyzed individu-
ally] (Fig.  1). Therefore, relative frequency of DVT in 
COVID-19 patients compared to non-COVID patients 
coming to the ED resulted in an unadjusted OR of 
0.98 (95% CI, 0.82–1.19) [1.10 (95% CI, 0.91–1.34) and 
0.79 (95% CI, 0.65–0.97) when comparisons were made 
with non-COVID-19 patients diagnosed during the pre-
COVID-19 and COVID-19 periods separately].
On the other hand, the annual standardized incidences of 
DVT were 98,38 per 100 000 COVID individuals and year 
and 42,93 per 100 000 non-COVID individuals per year 
(with partial standardized incidences of 33,25 and 52,15 
for the COVID and pre-COVID periods considered indi-
vidually). Accordingly, the OR for standardized incidence 
in COVID patients with respect to non-COVID patients 
was 2.20 (95% CI, 2.03–2.38) [2.80 (95% CI, 2.62–3.08) 
and 1.81 (95% CI, 1.67–1.96) for the COVID and pre-
COVID periods, respectively].
Clinical characteristics
The mean age of COVID patients with DVT (cases) was 
67 years: 61% were males, 11% had VTE history and 15% 
have active cancer. Other common comorbidities were 
hypertension (59%) and dyslipidemia (30%) (Table  1). 
The most frequent symptomatology was dyspnea (59%), 
lower limb pain/edema (58%), fever (41.1%), cough 
(36.6%) and chest pain (20.7%), and the median time 
from the symptom onset to ED consultation was 7 days. 
Table  2 shows the remaining clinical characteristics, as 
well as the vitals at ED arrival and laboratory findings. 
The median D-dimer levels in these patients were 
6.021 ng/mL and 68 patients (72.3%) had D-dimer lev-
els above 3000 ng/mL (Table  2). The location of DVT 
in complete compression Doppler ultrasound was only 
proximal in 40%, only distal in 38% and proximal and dis-
tal in 22% of cases.
Some statistically significant differences were found 
when cases were compared with controls (Tables  1–2), 
and the magnitude of these associations is shown in 
Table 3. The baseline characteristics in COVID patients 
associated with a higher risk of presenting DVT were 
age older than 65 years (OR, 1.50; 95% CI, 1.02–2.45) 
and having a history of VTE (2.98; 95% CI, 1.31–6.76), 
surgery or immobilization in the past month (OR, 3.28; 
95% CI, 1.51–7.12) and hypertension (OR, 1.73; 95% CI, 
1.12–2.67). Chest pain (OR, 1.8; 95% CI, 1.03–3.17) and 
desaturation (OR, 1.99; 95% CI, 1.23–3.21) at ED arrival, 
and some analytical disturbances, such as LDH values 
above 350  IU/L (OR, 2.0; 95% CI, 1.22–3.27) and leu-
cocyte count above 10 × 103cells/μL (OR, 4.65; 95% CI, 
2.91–7.43), were associated with a higher risk of present-
ing DVT in COVID patients. Of note, D-dimer levels 
greater than 5000 ng/mL were strongly associated with 
the presence of DVT (OR, 19.44; 95% CI, 10.53–35.88).
Outcomes
Nearly all the outcomes measured were worse in the cases 
than in the control group (Fig.  2). Specifically, COVID 
patients with DVT had a greater risk of the need for hos-
pitalization (OR, 2.96; 95% CI, 1.51–5.79), need for ICU 
admission (OR, 3.67; 95% CI, 1.93–6.97) and prolonged 
hospitalization (OR, 3.01; 95% CI, 1.88–4.82) compared 
to COVID patients without DVT, but the in-hospital 
mortality was similar. The sensitivity analysis including 
only COVID patients microbiologically confirmed by 
RT-PCR (80 cases and 246 controls) did not show differ-
ences in outcomes.
Discussion
The results of UMC-19-S
8
 show that around 1.50‰ of 
COVID-19 patients in EDs had DVT, being a relative 
frequency that is similar to what was observed in patients 
without COVID (1.52‰). However, a lower relative fre-
quency of DVT was recorded in non-COVID patients 
during the COVID period (OR, 0.79). Furthermore, 
the annual standardized incidence was also lower in 
non-COVID patients during the COVID period. These 
data could indicate that patients without COVID con-
sulted less in the EDs, and also that the active search for 
DVT in these patients was greater. This picture is sup-
ported by the fact that more than a third did not present 
Table 1 Baseline characteristics of patients with COVID-19 with 
deep venous thrombosis (cases) and comparison with patients 




N = 112 n (%)
Control group 
(COVID without 
DVT) N = 336
 n (%) P value
Demographics    
 Age (years) 68 (59–78) 65 (52–77) 0.07
  Age >65 69 (61.6) 169 (50.3) 0.03
Sex (female) 44 (60.7) 160 (47.6) 0.12
Risk factors for VTE    
 Obesity (clinically estimated) 23 (20.5) 51 (15.2) 0.18
 Active cancer 17 (15.2) 32 (9.5) 0.09
 Surgery/immobilization <1 month 14 (12.5) 14 (4.2) 0.002
 History of VTE 12 (10.7) 13 (3.9) 0.006
 Active smoker 8 (7.1) 22 (6.5) 0.86
 Estrogen use 1 (0.9) 4 (1.2) 0.79
Other comorbidities    
 Hypertension 66 (58.9) 152 (45.2) 0.01
 Dyslipidemia 34 (30.4) 112 (33.3) 0.56
 Diabetes mellitus 19 (17) 60 (17.9) 0.83
 Chronic kidney disease 8 (7.1) 21 (6.3) 0.73
 Coronary artery disease 7 (6.3) 26 (7.7) 0.60
 Cerebrovascular disease 7 (6.3) 23 (6.8) 0.82
 Dementia 6 (5.4) 29 (8.6) 0.26
 Chronic obstructive pulmonary 
disease
6 (5.4) 29 (8.6) 0.26
 Chronic liver disease 5 (4.5) 12 (3.6) 0.66
 Asthma 5 (4.5) 24 (7.1) 0.31
Bold P values denote statistical significance (P < 0.05).
COVID, coronavirus disease; DVT, deep venous thrombosis; VTE, venous throm-
boembolism.
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symptoms of DVT but had exceedingly high levels of 
D-dimer. A recent review of previous studies on VTE 
in COVID patients admitted to ICUs and general wards 
reported the presence of VTE in approximately 20% 
of patients with cumulative incidences of up to 35%, 
although it did not distinguish between DVT and pul-
monary embolism [18]. Two other recent studies found 
that the relative incidence of DVT compared to all VTE 
Table 2 Clinical and analytical characteristics of patients with COVID-19 with deep venous thrombosis (cases) and comparison with 
patients with COVID-19 without deep venous thrombosis (control group)
 
Cases (COVID with 
DVT) N = 112 n (%)
Control group (COVID 
without DVT) N = 336 n (%) P value
Symptoms at ED arrival    
 Lasting symptoms (days) [median (IQR)] 7 (3–14) 7 (3–10) 0.39
 Dyspnea 66 (58.9) 187 (55.7) 0.54
 Lower limb pain/edema 65 (58) – –
 Fever 46 (41.1) 198 (58.9) 0.001
 Cough 41 (36.6) 197 (58.6) <0.001
 Chest pain 23 (20.5) 42 (12.5) 0.03
 Diarrhea 17 (15.2) 55 (16.4) 0.76
 Expectoration 14 (12.5) 49 (14.6) 0.58
 Confusion 9 (8) 23 (6.8) 0.67
 Dysgeusia 9 (8) 26 (7.7) 0.91
 Anosmia 7 (6.3) 22 (6.5) 0.91
 Abdominal pain 6 (5.4) 17 (5.1) 0.90
 Vomiting 6 (5.4) 25 (7.4) 0.45
 Headache 6 (5.4) 39 (11.6) 0.05
 Syncope 3 (2.7) 14 (4.2) 0.47
 Rhinorrhea 2 (1.8) 23 (6.8) 0.04
 Hemoptysis 2 (1.8) 2 (0.6) 0.24
Signs at ED arrival    
 Temperature (°C) [median (IQR)] 36.5 (36.0–37.2) 36.6 (36.0–37.3) 0.45
  Temperature at ED arrival >38 °C 10 (9) 35 (10.6) 0.62
 SBP (mmHg) [median (IQR)] 131 (116–144) 125 (115–140) 0.36
 Heart rate (bpm) [median (IQR)] 92 (85–107) 88 (78–100) 0.002
  Heart rate >100 bpm 38 (33.9) 86 (26.1) 0.11
 Respiratory rate (bpm) [median (IQR)] 20 (16–24) 18 (16–22) 0.07
  Respiratory rate >20 bpm 58 (53.2) 146 (45.2) 0.14
 Room air pulsioxymetry (%) [median (IQR)] 95 (91–97) 96 (93–98) 0.003
  Room air pulsioxymetry <96% 84 (75) 202 (61) 0.008
Laboratory findingsa (n of cases/n of controls)    
 C-reactive protein (mg/dL) [median (IQR)] (102/289) 7.75 (3.36–16.6) 5.90 (1.8–12.1) <0.001
  C-reactive protein >5 66 (64.7) 162 (56.1) 0.12
 Creatinine (mg/dL) [median (IQR)] (106/307) 0.86 (0.72–1.13) 0.87 (0.71–1.10) 0.80
 ASAT (UI/L) [median (IQR)] (76/253) 29 (19–43) 30 (22–48) 0.13
 Bilirubin (mg/dL) [median (IQR)] (70/219) 0.7 (0.5–1.0) 0.5 (0.3–0.7) <0.001
 LDH (UI/L) [median (IQR)] (66/235) 350 (253–526) 276 (70–1187) <0.0001
  LDH >350 34 (51.5) 60 (25.6) <0.001
 Procalcitonin (ng/mL) [median (IQR)] (55/131) 0.1 (0.04–0.31) 0.1 (0.06–0.21) 0.89
 Hemoglobin (g/L) [median (IQR)] (107/308) 13.9 (12.7–15.1) 13.8 (6.8–17.7) 0.72
  Hemoglobin <10 2 (1.9) 14 (4.5) 0.22
 Leucocytes count [median (IQR)] (110/308) 9.8 (7.3–12.1) 6.6 (4.9–9.0) <0.0001
  Leucocytes >10 54 (49.1) 56 (18.2) <0.001
 Lymphocytes count [median (IQR)] (104/293) 1.1 (0.8–1.7) 1.1 (0.8–1.6) 0.34
 Platelets [median (IQR)] (108/307) 232 (183–324) 206 (161–258) <0.0001
 Platelets <200 39 (36.1) 144 (46.9) 0.05
 APTT (s) [median (IQR)] (73/200) 29.4 (27.2–32.3) 29.7 (26.5–33.3) 0.58
 Prothrombine time (s) [median (IQR)] (66/217) 13.5 (12.0–14.5) 12.5 (11.5–14.0) 0.05
 Fibrinogen (g/L) [median (IQR)] (53/111) 500 (386–664) 500 (469–614) 0.61
 D-dimer (ng/mL) [median (IQR)] (96/247) 6021 (2270–10035) 680 (390–1275) <0.0001
  D-dimer >10000 24 (25.5) 8 (3.3) <0.001
  D-dimer >5000 57 (60.6) 17 (7.1) <0.001
  D-dimer >3000 68 (72.3) 26 (10.8) <0.001
Chest X-ray    
 Cardiomegaly 15 (16) 34 (10.8) 0.18
 Interstitial lung infiltrates 51 (52.6) 144 (73.8) 0.14
 Ground-glass lung opacities 57 (58.8) 186 (57.1) 0.76
 Pleural effusion 7 (7.5) 14 (4.4) 0.22
Characteristics DVT in CCUS    
 Proximal 35 (40.2) – –
 Distal 33 (37.9) – –
 Proximal and distal 19 (21.8) – –
Disposition    
 Discharge from ED 10 (8.9) 83 (24.7) <0.001
Bold P values denote statistical significance (P < 0.05).
APTT, activated partial thromboplastin time; ASAT, aspartate aminotransferase; CCUS, complete compression Doppler ultrasound; COVID, coronavirus disease; DVT, 
deep venous thrombosis; ED, emergency department; IQR, interquartile range; LDH, lactate dehydrogenase; SBP, systolic blood pressure.
aAt ED arrival.
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events in COVID patients ranged from 1.4 [13] to 13% 
[9] of all VTE episodes, being percentages which very 
much lower than those reported in the general popula-
tion (non-COVID patients), in which DVT is present 
in up to 53% of VTE episodes [19]. Taking all these 
data together with our results, we believe that COVID 
patients do not have an increased risk of presenting this 
type of VTE. In summary, the incidence of confirmed 
DVT in patients with COVID who attend the ED, in the 
same way as pulmonary embolism [20], does not seem to 
be increased.
The clinical characteristics of COVID patients that were 
found to be associated with a higher risk of presenting 
DVT were older age and having a previous history of 
VTE, surgery or immobilization during the last month, 
similar to what is observed in the general population 
[21]. Interestingly, COVID patients in the ED presented 
fewer symptoms related to the infectious process such as 
fever, cough but more frequently had analytical inflam-
matory parameters such as increased white blood cell 
count and LDH values. Similar data have been reported 
in hospitalized patients with COVID and DVT and sug-
gest a multifactorial cause or association with advanced 
age, infectious processes, and inflammatory and coagulo-
pathic state [22]. Significantly, we found D-dimer levels 
above 5000 to be strongly associated with the presence 
of DVT in COVID patients. The association of disease 
severity and mortality in COVID-19 with higher D-dimer 
levels has been reported in several studies [23], but it is 
a nonspecific marker that can rise in many conditions, 
including VTE. In this sense, several retrospective pub-
lications found a relationship between higher D-dimer 
levels and VTE (both DVT and pulmonary embolism) in 
COVID-19 patients. For this reason, some authors sug-
gest the need for a targeted search for DVT or pulmonary 
embolism if D-dimer levels rise above 2000–4000 µg/L 
[24]. However, recent guidelines do not suggest the use 
of biomarkers in the diagnostic evaluation for suspected 
DVT or pulmonary embolism in in-patient populations 
[25]. In this sense, our findings are significant because 
they have been obtained in the context of outpatients 
assessed in the ED.
Nearly 40% of DVTs are asymptomatic in COVID 
patients. This can be explained in that most hospital pro-
tocols created in Spain at the beginning of the outbreak 
indicated the search for DVT or if the D-dimer levels 
were high. Furthermore, this incidence is higher than 
that observed in other studies. In a prospective study 
in patients admitted to a general ward with COVID-19 
pneumonia and elevated D-dimer levels, the incidence 
of asymptomatic DVT was similar to that described in 
other non-COVID series, being around 15% [11,26]. 
Remarkably, we found less frequency for simultaneous 
proximal and distal DVT in patients with COVID-19. 
This fact, combined with the finding of a lower pulmo-
nary embolism thrombus load in COVID patients, may 
indicate a different pathophysiological process, which 
would be more related to a procoagulant state than to 
a thromboembolic mechanism. Similar results have 
recently been reported in a larger study with pulmonary 
embolism patients, suggesting a different phenotype of 
thrombotic disease [27,28].
Nearly all the outcomes assessed in UMC-19-S
8
 were 
worse for COVID patients with DVT compared to the 
control group, even after adjustment for age and sex. But 
in-hospital mortality was similar. The presence of a DVT 
may require the need for hospitalization and prolong the 
hospital stay, probably related to anticoagulation control. 
Furthermore, these patients probably have a more severe 
COVID (desaturation, increased LDH and D-dimer) in 
addition to greater comorbidity such as older age. The 
absence of differences in mortality could indicate that 
the presence of DVT itself in COVID patients is not a 
risk factor for mortality.
Limitations
This study has several limitations. First, the relative 
frequency of DVT implies both symptomatic DVT 
and asymptomatic DVT, and thus, comparisons with 
epidemiological studies may not be valid. Second, in 
many cases, the diagnosis of COVID-19 was based on 
clinical and radiological findings with no microbiological 
confirmation. However, the sensitivity analysis includ-
ing only COVID patients microbiologically confirmed 
by RT-PCR did not found differences in outcomes. 
Third, we did not adjust our estimates for all relevant 
patient-related or disease-related factors, especially pul-
monary embolism, and this could somewhat alter the 
estimations presented in the current study. This could 
also be true for the estimations of outcomes, because 
the limited number of cases included in our study and 
adverse events observed were only adjusted for age and 
sex. Fifth, although the case record form was standard-
ized, as a retrospective study, there was no monitoring of 
data collection methods.
Table 3 Magnitude of statistically significant associations found 





Risk factors for developing DVT in COVID patients 
(respect to COVID patients not developing DVT)
  
D-dimers >5000 ng/mL 19.44 10.53–35.88
Leucocyte count >10 cells/μL 4.65 2.91–7.43
Surgery/immobilization <1 month 3.28 1.51–7.12
History of VTE 2.98 1.31–6.74
Lactate dehydrogenase >350 UI/L 2.00 1.22–3.27
Room air pulsioxymetry at ED arrival <96% 1.99 1.23–3.21
Complaining with chest pain 1.80 1.03–3.17
Hypertension 1.73 1.12–2.67
Age >65 1.50 1.02–2.45
Complaining of fever 0.48 0.31–0.75
Complaining of cough 0.40 0.26–0.63
Complaining of rhinorrhea 0.26 0.05–1.06
COVID, coronavirus disease; DVT, deep venous thrombosis; ED, emergency 
department; VTE, venous thromboembolism.
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Conclusion
Despite these limitations, we conclude that the incidence 
of DVT in COVID patients attending the ED is similar 
than that observed in non-COVID patients. In some cir-
cumstances, this incidence could be increased, especially 
in COVID patients with a history of VTE, recent surgery/
immobilization and D-dimer levels above 5000 ng/mL. 
Patients with COVID developing DVT have poor prog-
nosis but in-hospital mortality is similar to that observed 
in COVID patients without DVT.
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Fig. 2
Outcomes of patients with COVID-19 and deep venous thrombosis (DVT) (cases) compared with patients with COVID-19 without DVT (control 
group), unadjusted and adjusted for age and sex. *Results of the sensitivity analysis including only COVID patients microbiologically confirmed by 
RT-PCR (80 cases and 246 controls).
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